DYRK1B and pancreatic neoplasm: In the present study we show that interfering with DYRK1B dramatically impairs SMO-independent GLI1 expression in RAS mutant pancreatic cancer cells and phenocopies the anti-tumorigenic effect of GLI1 targeting [16].